Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Prostate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    897 result(s) found for: Prostate. Displaying page 16 of 45.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2020-000121-37 Sponsor Protocol Number: 2020-PSMA Start Date*: 2020-06-09
    Sponsor Name:CYCLOPHARMA
    Full Title: A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
    Medical condition: Patients with histopathologically confirmed prostate adenocarcinoma per original diagnosis and subsequent definitive therapy, with first biochemical recurrence
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000701-11 Sponsor Protocol Number: CA180227 Start Date*: 2008-11-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer Revised Protocol 03 incorporating A...
    Medical condition: castration-resistant metastatic prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IE (Completed) HU (Completed) FR (Completed) IT (Completed) GB (Completed) CZ (Completed) FI (Completed) SE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005046-55 Sponsor Protocol Number: 20151104 Start Date*: 2016-08-23
    Sponsor Name:Umeå University Hospital
    Full Title: Evaluation of [68Ga]PSMA PET/MRI in intermediate and high risk prostate cancer – a comparison with mpMRI, [11C]ACE PET/CT and histopathological validation
    Medical condition: Medium and high risk prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002796-32 Sponsor Protocol Number: BAY 38-9456 / 11863 Start Date*: 2005-10-17
    Sponsor Name:Bayer Healthcare AG
    Full Title: A randomized, double-blind, placebo-controlled, multi-center, parallel group study to assess the efficacy of vardenafil in the treatment of symtomatic Benign Prostatic Hyperplasia
    Medical condition: Benigne Prostatic Hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10004446 LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001137-16 Sponsor Protocol Number: LPC-003 Start Date*: 2011-04-20
    Sponsor Name:LIDDS AB
    Full Title: An open, single dose, antitumor effect study of 2-hydroxyflutamide as a controlled release product (Liproca® Depot), injected into the prostate in patients with localized prostate cancer.
    Medical condition: Localized prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Prematurely Ended) FI (Completed)
    Trial results: View results
    EudraCT Number: 2018-001267-22 Sponsor Protocol Number: 65593 Start Date*: 2019-10-10
    Sponsor Name:Radboud University Medical Center
    Full Title: F18-PSMA-1007 PET for early biochemical recurrence of prostate cancer, comparison with 18F-Fluciclovine.
    Medical condition: Patients treated for non-metastasized prostate cancer with a biochemical recurrence of prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003905-31 Sponsor Protocol Number: RF-2021-12372278 Start Date*: 2023-07-14
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer
    Medical condition: Patients with clinical suspicion of clinically relevant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001253-41 Sponsor Protocol Number: GOIM16002-CABONESTUDY Start Date*: 2018-03-12
    Sponsor Name:GRUPPO ONCOLOGICO DELL'ITALIA MERIDIONALE
    Full Title: Impact of cabazitaxel on metastatic bone disease in patients with castration resistant prostate cancer previously treated with docetaxel
    Medical condition: 1. Histologically or cytologically confirmed adenocarcinoma of prostate that is resistant to hormone therapy and previously treated with a docetaxel containing regimen.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000123-12 Sponsor Protocol Number: 2020110469 Start Date*: 2021-06-22
    Sponsor Name:Odense University Hospital
    Full Title: PRISMA-PET – Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging.
    Medical condition: Newly diagnosed prostate cancer, PET/CT scan used to stage newly diagnosed prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018015-11 Sponsor Protocol Number: IMCLCP15-0805 Start Date*: 2010-10-20
    Sponsor Name:ImClone LLC
    Full Title: A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 plus Mitoxantrone plus Prednisone or Mitoxantrone plus Prednisone in Metastatic Castration-Refractory Prostate Cancer (CR...
    Medical condition: Metastatic Castration-Refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-001834-33 Sponsor Protocol Number: XL184–307 Start Date*: 2012-08-01
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior ...
    Medical condition: Metastatic Castration-resistant Prostate Cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) NL (Completed) SE (Completed) AT (Completed) IE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003022-92 Sponsor Protocol Number: 9785-CL-0403 Start Date*: 2014-04-29
    Sponsor Name:Astellas Pharma Global Development, Inc.
    Full Title: A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutam...
    Medical condition: Medical condition: metastatic castration-resistant prostate cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DE (Completed) HU (Completed) GB (Completed) BE (Completed) FI (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000142-35 Sponsor Protocol Number: UC-0160/1105 Start Date*: 2014-05-19
    Sponsor Name:UNICANCER
    Full Title: A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-na...
    Medical condition: metastatic hormone-naïve prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) ES (Ongoing) IE (Completed) BE (Completed) IT (Completed) DE (Completed) RO (Completed) GR (Ongoing) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020821-41 Sponsor Protocol Number: MDV3100-03 Start Date*: 2011-02-10
    Sponsor Name:Medivation, Inc., a wholly owned subsidiary of Pfizer Inc.
    Full Title: PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer W...
    Medical condition: Chemotherapy-Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) NL (Completed) ES (Completed) SE (Completed) AT (Completed) FI (Completed) DK (Completed) SK (Completed) IT (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004730-42 Sponsor Protocol Number: IQVIA-ODYS-001-LZA45541 Start Date*: 2022-10-24
    Sponsor Name:IQVIA RDS FRANCE SAS
    Full Title: Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in c...
    Medical condition: Long term potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among ne...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070999 Intraductal papillary mucinous neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 100000004871 10008953 Chronic liver disease LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003967-37 Sponsor Protocol Number: CV-9103-001 Start Date*: 2008-12-08
    Sponsor Name:CureVac GmbH
    Full Title: Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease
    Medical condition: patients with hormone-refractory prostate cancer (HRPC) with rising PSA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002725-74 Sponsor Protocol Number: COU-AA-004 Start Date*: 2007-07-16
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
    Medical condition: HRPC (Hormone refractory prostate cancer) refractory to androgen deprivation and Docetaxel based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005967-27 Sponsor Protocol Number: ASL605LIOM03 PROMET Start Date*: 2006-10-31
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: Study pilot of metronomic chemotherapy with ciclofosfamide, celecoxib and desametasone in patients with diagnosis of carcinoma of the refractory ormon prostate in advanced stage appraisal pharmac...
    Medical condition: ORMONO REFRACTORY CARCINOMA OF PROSTATE IN ADVANCED STAGE
    Disease: Version SOC Term Classification Code Term Level
    6.1 10007280 PT
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003121-42 Sponsor Protocol Number: CHDR1635 Start Date*: 2019-11-28
    Sponsor Name:Enceladus Pharmaceuticals BV
    Full Title: A Phase I-IIa, Open label, Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate as Monotherapy in Pa...
    Medical condition: Castration resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015116-17 Sponsor Protocol Number: ProMet-3 Start Date*: 2009-12-23
    Sponsor Name:ARCO
    Full Title: Phase II study with pharmacokinetic and pharmacodynamic evaluations of metronomic chemotherapy with oral Vinorelbine and Dexamethasone in advanced castraction-resistant prostate cancer patients
    Medical condition: Patients with advanced metastatic prostatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 LLT
    Population Age: Infants and toddlers, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 05:57:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA